Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies that target the immune system, with a focus on mast-cell-driven diseases. Its lead candidate, barzolvolimab, is being studied in chronic urticaria and other inflammatory conditions where mast cells play a central role. The pipeline centers on biologics designed for patients with limited treatment options in allergy and immunology.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0.7 | — | -53.8 | — |
| Q2 2025 | 0.7 | — | -56.6 | — |
| Q3 2025 | 0 | — | -67 | — |
| Q4 2025 | 0.1 | — | -81.3 | — |
| Q1 2026 | 0 | -97.8% | -78.7 | — |
| Q2 2026 | 0 | -97% | -73.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: WaFd, Inc. (WAFD), CleanSpark, Inc. (CLSK), Encore Capital Group, Inc. (ECPG), Viridian Therapeutics, Inc. (VRDN), Pony AI Inc. (PONY), Bel Fuse Inc. (BELFA)